I sit down with Alison Bateman-House, PhD, MPH, MA, from NYU, to discuss the details of the “Right To Try Act” a year after it was signed into law. Was it a good idea? Do patients stand to benefit? What led to this initiative and how does this help clinical trial enrollment, if at all?
If you have any interest in healthcare policy and how it might affect patient care and healthcare delivery, this episode is for you.
This podcast is produced by the Journal of Clinical Pathways.
Dr. Joe Mikhael, Chief Medical Officer of the International Myeloma Foundation (IMF) and Professor at TGen, takes us beyond his medical career to explore the personal experiences that have shaped his journey in oncology. Dr. Mikhael discusses the IMF’s targeted strategies for reducing health disparities among diverse ethnic and racial groups affected by myeloma, shedding
Tom Beer, Chief Medical Officer of the Multi-Cancer Early Detection (MCED) program at Exact Sciences, delves into the groundbreaking science behind MCED tests, which use advanced biomarkers for early detection of multiple cancer types. On this Healthcare Unfiltered episode, he explains who may be eligible for these tests, how to interpret results to avoid unnecessary
In this special episode, I give up the microphone to guest host Kelly Ryerson, who takes over the show asking questions about my new book “The Cancer Journey.”
